Etoposide Solution for Injection

Cytotoxic Agent

Etoposide
  • Etoposide contains Etoposide 20 mg / 5 mL
  • Etoposide Solution for Injection is available in a 5 mL single-use clear glass vial containing 100 mg etoposide
  • Etoposide is fully funded on the Pharmaceutical Schedule

Etoposide solution for injection, in combination with other approved chemotherapeutic agents, is indicated as first-line treatment in patients with small cell lung cancer.

It is also indicated for the treatment of Hodgkin’s disease; malignant (non-Hodgkin’s) lymphomas, especially of the histiocytic variety; acute non-lymphocytic leukaemia; and testicular tumours (both as first-line combination regimens and for the treatment of refractory testicular tumours).

Etoposide, PRESCRIPTION MEDICINE. Etoposide Solution for Injection is available in 100 mg (5 mL) sterile single, clear glass vials.

Etoposide Solution for Injection is indicated in the treatment of: Small Cell Lung Cancer (Etoposide Solution for Injection is indicated for the first-line treatment of small cell lung cancer in use with additional chemotherapeutic agents), Hodgkin’s Disease; Malignant (non-Hodgkin’s) lymphomas, particularly of the histiocytic range; acute non-lymphocytic leukaemia, and testicular tumours (Etoposide Solution for Injection is indicated both as the first-line combination regimens and for the treatment of refractory testicular tumours).

Etoposide Solution for Injection has risks and benefits. An experienced physician in the use of oncological chemotherapy should supervise the administration of Etoposide Solution for Injection. Discuss with your doctor if you have any concerns.

Etoposide Solution for Injection is fully funded. Standard doctor’s fees and pharmacy charges apply.

Distributed by REX Medical Ltd, Auckland, New Zealand.